Low-dose spironolactone in the management of resistant hypertension: A surveillance study

Journal of Hypertension

Volumn 25, Issue 4, 2007, Pages 891-894

  Lane, Deirdre A ^a   Shah, Sarah ^a   Beevers, D Gareth ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Resistant hypertension; Spironolactone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE RESISTANCE; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INDIGESTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 33947162019     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328014954d     Document Type: Article

References (19)

1. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126:761-767.
2. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al., for the HOT study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
3. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004 - BHS IV. J Hum Hypertens 2004; 18:139-185.
4. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-661.
5. Marshall T. How many antihypertensives do patients need to achieve a target blood pressure? J Hum Hypertens 2005; 19:317-319.
6. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930.
7. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15:333-339.
8. Pitt B, Zannan F, Renne WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
9. Ramsay LE, Hettiarachichi J, Fraser R, Morton JJ. Amiloride, spironolactone and potassium chloride in thiazide treated hypertensive patients. Clin Pharmacol Ther 1980; 27:533-543.
10. Anon. Spironolactone: no longer for hypertension. Drug Ther Bull 1988; 26:88.
11. Burnier M, Scheider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19:335-341.
12. Degoulet P, Menard J, Vu HA, Golmard JL, Devries C, Chatellier G, et al. Factors predictive of attendance at clinic and blood pressure control in hypertensive patients. BMJ 1983; 287:88-93.
13. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001; 14:1263-1269.
14. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
15. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40:117-123.
16. Freestone S, Ramsay LE. Frusemide and spironolactone in resistant hypertension: a controlled trial. J Hypertens 1988; 1 (Suppl. 2):326-328.
17. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertenive effect, and adverse biochemical effects. BMJ 1990; 300:975-978.
18. Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs 2005; 5:171-183.
19. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327:147-149.